Advances in radiotherapy technology for pediatric cancer patients and roles of medical physicists: COG and SIOP Europe perspectives.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
05 2021
Historique:
revised: 27 03 2020
received: 30 01 2020
accepted: 02 04 2020
entrez: 5 4 2021
pubmed: 6 4 2021
medline: 25 9 2021
Statut: ppublish

Résumé

Over the last two decades, rapid technological advances have dramatically changed radiation delivery to children with cancer, enabling improved normal-tissue sparing. This article describes recent advances in photon and proton therapy technologies, image-guided patient positioning, motion management, and adaptive therapy that are relevant to pediatric cancer patients. For medical physicists who are at the forefront of realizing the promise of technology, challenges remain with respect to ensuring patient safety as new technologies are implemented with increasing treatment complexity. The contributions of medical physicists to meeting these challenges in daily practice, in the conduct of clinical trials, and in pediatric oncology cooperative groups are highlighted. Representing the perspective of the physics committees of the Children's Oncology Group (COG) and the European Society for Paediatric Oncology (SIOP Europe), this paper provides recommendations regarding the safe delivery of pediatric radiotherapy. Emerging innovations are highlighted to encourage pediatric applications with a view to maximizing the therapeutic ratio.

Identifiants

pubmed: 33818892
doi: 10.1002/pbc.28344
pmc: PMC8030241
mid: NIHMS1591004
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28344

Subventions

Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180803
Pays : United States

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):491-7
pubmed: 18207663
J Radiol Prot. 2015 Sep;35(3):611-28
pubmed: 26226081
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62
pubmed: 23790512
Radiother Oncol. 2012 Jul;104(1):45-51
pubmed: 22560714
Radiat Oncol. 2018 Oct 11;13(1):198
pubmed: 30305118
J Med Imaging Radiat Sci. 2018 Jun;49(2):153-163
pubmed: 32074033
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):273-9
pubmed: 18786784
Radiat Oncol. 2017 Jan 26;12(1):28
pubmed: 28126030
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):978-92
pubmed: 27026304
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1771-6
pubmed: 21621338
Phys Med Biol. 2017 Oct 04;62(20):8178-8196
pubmed: 28901947
Acta Oncol. 2019 Feb;58(2):243-250
pubmed: 30523729
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):28-37
pubmed: 30170102
Phys Med Biol. 2016 Nov 7;61(21):7812-7832
pubmed: 27754983
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):227-237
pubmed: 28816151
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):71-8
pubmed: 25028286
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1470-5
pubmed: 17208387
Int J Part Ther. 2018 Fall;5(2):1-10
pubmed: 30800718
Clin Oncol (R Coll Radiol). 2019 Mar;31(3):199-207
pubmed: 30670336
Acta Oncol. 2018 Jul;57(7):941-949
pubmed: 29457751
Med Phys. 2018 Jul;45(7):3287-3296
pubmed: 29786862
Cancer Radiother. 2017 Apr;21(2):124-129
pubmed: 28377061
Med Phys. 2012 May;39(5):2761-4
pubmed: 22559647
Br J Radiol. 2015 Sep;88(1053):20150134
pubmed: 26043157
Acta Oncol. 2015;54(9):1245-50
pubmed: 26390238
Phys Med Biol. 2019 Jan 08;64(2):025004
pubmed: 30523932
Med Phys. 2013 May;40(5):051711
pubmed: 23635259
Acta Oncol. 2018 Sep;57(9):1240-1249
pubmed: 29698060
Radiat Oncol. 2018 Sep 12;13(1):173
pubmed: 30208936
Med Phys. 2012 Feb;39(2):1079-91
pubmed: 22320818
Med Phys. 2018 Nov;45(11):e1036-e1050
pubmed: 30421803
Pract Radiat Oncol. 2015 Mar-Apr;5(2):85-92
pubmed: 25413415
J Med Imaging Radiat Sci. 2015 Jun;46(2):134-140
pubmed: 31052086
Radiother Oncol. 2008 Nov;89(2):135-40
pubmed: 18707783
Radiat Oncol. 2008 Apr 19;3:9
pubmed: 18423047
Lancet Oncol. 2019 Mar;20(3):e155-e166
pubmed: 30842059
Acta Oncol. 2018 Jul;57(7):902-907
pubmed: 29488426
Med Phys. 2014 May;41(5):051711
pubmed: 24784377
Radiat Oncol. 2018 Mar 27;13(1):56
pubmed: 29587881
Radiother Oncol. 2019 Feb;131:127-134
pubmed: 30773179
Pract Radiat Oncol. 2015 Mar-Apr;5(2):e87-94
pubmed: 25413402
Med Phys. 2008 Jan;35(1):206-15
pubmed: 18293576
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):716-21
pubmed: 18676089
Phys Med Biol. 2019 Feb 25;64(5):055010
pubmed: 30669135
Phys Med Biol. 2018 Nov 12;63(22):22TR02
pubmed: 30418942
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7
pubmed: 16618572
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):394-403
pubmed: 26678659
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):761-7
pubmed: 22818413
Radiat Oncol. 2016 Mar 22;11:46
pubmed: 27000180
Radiother Oncol. 1999 Jun;51(3):257-71
pubmed: 10435821
Radiother Oncol. 2016 Apr;119(1):137-44
pubmed: 26975241
Front Radiat Ther Oncol. 2011;43:382-394
pubmed: 21625164
Pediatr Blood Cancer. 2018 Sep;65(9):e27112
pubmed: 29745023
Acta Oncol. 2015 Apr;54(4):563-6
pubmed: 25410591
Int J Part Ther. 2018 Spring;4(4):20-27
pubmed: 30214913
Med Phys. 2018 Nov;45(11):e1011-e1023
pubmed: 30421811
Radiother Oncol. 2018 Dec;129(3):527-533
pubmed: 30172456
Phys Med Biol. 2013 Sep 21;58(18):6337-53
pubmed: 23965339
Pract Radiat Oncol. 2019 Jan;9(1):e110-e117
pubmed: 30355524
Med Phys. 2017 Jun;44(6):2332-2344
pubmed: 28295434

Auteurs

Chia-Ho Hua (CH)

Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Anthony E Mascia (AE)

Department of Radiation Oncology, University of Cincinnati, Cincinnati, Ohio.

Enrica Seravalli (E)

Department of Radiotherapy, University Medical Center Utrecht, The Netherlands.

Antony J Lomax (AJ)

Center for Proton Therapy, Paul Scherrer Institute, PSI Villigen, Switzerland.

Klaus Seiersen (K)

Danish Centre for Particle Therapy, Aarhus, Denmark.

Kenneth Ulin (K)

Department of Radiation Oncology, University of Massachusetts, Worcester, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH